Index

abortion 136
ageing 37
ambient risk 33
amniocentesis 106, 111, 112, 113, 114, 115, 116, 125
animal experiments 129
anomalous findings 50–51, 57
antenatal screening 11–12
amniocentesis 106, 111, 112, 113, 114, 115, 116, 125
choice 105, 121, 122
conflict 116
conversation analytic studies 105, 106
decision-making 105, 106, 121, 123
denmark 122
don’s syndrome 108, 109, 110, 116, 117
first trimester prenatal risk assessment (FTPRA) 122–9
high-risk results 106, 108, 114
Hong Kong 107, 108, 109, 117
knowledge production 123, 132, 133
resistance 128–30
non-directiveness 106, 112, 121, 122, 123, 130–131, 132
presumed acceptance 106
social characteristics of patients 4, 5, 11, 107, 109, 115, 117, 118
ultrasound scans 116, 124–7
bonding scans 11, 12, 136, 138–40, 142, 146, 147
collaborative coding 142–6, 147
communicating risk with care 127–31, 132
feminist critiques 136, 137, 139–40, 142, 145
fetal facial expressions 140, 144, 147
fetal personality 143–4
fetal resemblance 142–3
medical and social meanings 137–8, 146, 148
potential harm 138, 139
sonographer as expert guide 141–2, 146–7
sonographers’ body language 127
speaking to and for the fetus 144–5
technological and embodied knowledge 145–6, 147, 148
armed forces 19–20, 27
see also non-attendance
autonomous decision-making 28, 29, 122, 132
blood pressure 25
blood tests 35
Blume, S. 76
bonding scans 11, 12, 136, 138–40, 142, 146, 147
breast screening 3, 4, 26, 28
bridging work 9, 10, 48, 52, 53, 56–7
cancer screening 21, 60
cervical see cervical screening; HPV
prostate see prostate cancer detection; prostate-specific antigen tests
cardiovascular disease 20, 22, 23
case finding 27–8
cervical screening 4, 5–6, 10, 21
diagnostics companies 73
see also Digene
molecularisation 73, 79, 84, 86
Pap smear 73, 74–5, 79, 84, 86
see also HPV
choice 105, 121, 122
see also autonomous decision-making: informed choice
cholesterol 34–5, 36, 37, 38, 39, 40–41, 42
chronic illness 21–2, 42
citizenship 7, 68
corruption 122
commercial markets 74, 75, 85
communicable diseases 19, 20, 27
communication 127–31, 132
conversation analysis 11, 105, 106
corporatisation 74, 75, 85
costs of screening 2, 3
decision-making 6–7, 11, 105, 106, 121, 123
denmark 122
despret, vinciane 129, 131
diabetes 20
diagnosis 2, 50
diagnostics companies 10, 73, 74
see also Digene
digene 73, 74, 75
collaboration with Kaiser Permanenete 79, 81
HC2 test 79–80, 81
hybrid capture test 75, 78
protecting market share 82–4
strategic success 84, 85–6
DNA patenting 73, 74
don’s syndrome 108, 109, 110, 116, 117
embodiment 6, 38, 145–6, 147, 148
epidemiology 94

ethnographic research 8, 10, 12, 48, 92
eugenics 105
expectations management 61, 69–70
experience of illness framework 34
methodology 34–6
false-positives/negatives 2, 4, 26
feminist critiques 136, 137, 139–40, 142, 145
fetal chromosomal abnormalities 105
see also antenatal screening; Down’s syndrome
fetal imaging see ultrasound: antenatal screening
first trimester prenatal risk assessment (FTPRA) 122–9
Foucault, Michel 61, 68, 123
Framingham study 22
genetic counselling 106
遗传性筛查 3–4, 10, 43
ambiguities 49
cancer 60
prostate cancer biomarker 65–6
prostate cancer genome-wide association studies 66–7
clinical implications 48, 49, 50
diagnostics companies 73, 74
see also Digene
medium chain acyl-CoA dehydrogenase deficiency see medium chain acyl-CoA dehydrogenase deficiency
predictive 3, 69
genome-wide association studies 66–7
genomic data 73, 74
globalisation 8
Goody, Jade 4
governance 61, 68, 69, 70
harms of screening 24–7
health risk see risk
HIV screening 26
Hong Kong 107, 108, 109, 117
HPV (human papilloma virus)
diagnostic testing 75
adoption (1999–2003) 80–81
Digene see Digene
exploration (1983–1988) 77
growth (2003 to the present) 81–2
HC2 test 79–80, 81
Hybrid Capture test 75, 78
ViraPap 77–8
Pap smear 73, 74–5, 79, 84, 86
see also cervical screening
hypertension 25
immutable mobiles 128
informed choice 6–7
prostate-specific antigen tests 63, 68
knowledge management 69
knowledge production 123, 132, 133
resistance 128–30
Latour, B. 128
lifestyle problems 117
lobby groups 4
market forces 74, 75, 85
measured vulnerability 8, 9, 39, 42–3, 44
media reporting 33, 69
medical journals 17
medium chain acyl-CoA dehydrogenase deficiency 48, 51
diagnosis 51–3
nuanced and diverse understanding 57
outcomes 55–6
severity and incidence 53–4
treatment 54–5
metabolic diseases 47–8
diabetes 20
medium chain acyl-CoA dehydrogenase deficiency see medium chain acyl-CoA dehydrogenase deficiency
migrants: TB screening see TB screening: migrant screening
military contexts 19–20, 27
misdiagnosis 2, 26
Mitchell, L.M. 137, 143, 144, 147
molecularisation 9, 10, 73, 74, 79, 84, 86
moral obligation 6
mosquitoes 18
multifactorial causation 23, 28, 29
multi-phasic screening 23–4
newborn screening 3, 9–10
anomalies due to population screening 50–51, 57
clinical implications 48, 50
expansion 47, 49
metabolic diseases 47–8
medium chain acyl-CoA dehydrogenase deficiency see medium chain acyl-CoA dehydrogenase deficiency
NHS provision 2
non-attendance 4, 25–6
see also attendance
non-directiveness 11, 106, 112, 121, 122, 123, 130–131, 132
normative expectations 6
Pap smear 73, 74–5, 79, 84, 86
see also HPV
patient autonomy 28, 29, 122, 132
population-based medical screening 2, 5
anomalies 50–51, 57
power relations 6, 61, 68, 121
precision medicine 74
predictive genetic testing 3, 69
prenatal screening see antenatal screening
prevention 22, 122
private patients 107
private provision 2, 75
prostate cancer detection
  genetic biomarker 65–6
  genome-wide association studies 66–7
  predictive genome variant-based screening 69
prostate-specific antigen see prostate-specific antigen
tests
  technology governance 61, 68, 69, 70
prostate-specific antigen tests 4, 10
dilemmas 62
  efficacy and controversy 43, 60–61, 63–4
  experience of risk and compromised health
  35, 36, 37, 38, 39, 40, 41–2, 62
  informed choice 63, 68
  prostate-specific antigen biomarker 63–4
targeted screening 64, 68
  uncertainty 40, 42, 62, 64, 68
psychiatric screening 19
psychological factors 4–5, 25
radiography 17–18, 19, 20
Rehmann-Sutter, C. 123, 130
responsible citizenship 6, 68
risk 7, 9
  chronic illness and 42
  communication 127–31, 132
  expectations and 61, 69–70
  experience of illness framework 34
  methodology 34–6
  governance and 61, 68, 69, 70
lay understanding 33
prenatal screening 11
social condition of compromised health status 34, 36
  altered health status 36–7
  identity and embodiment 38
  indicator of advancing age 37
  meanings of numbers 40–42
  measured vulnerability 39, 42–3, 44
  pervasiveness of risk 37–8
  vulnerability and uncertainty 39–40, 42
statistical 33, 34
risk factors 22, 33–4
multifactorial causation 23, 28, 29
Roma communities 95, 96, 97, 98, 99, 100
Sandelowski, M. 147, 148
school medical examinations 18–19, 27
screening
costs and harms 2, 3, 24–7
  history 9
  armed forces 19–20, 27
  doctor-patient relationship 27–9
  linear model 22, 24
  multiphasic screening 23–4
  postwar 20–22
school medical examinations 18–19, 27
uses of the term 17–19
X-rays 17–18, 19, 20
justification 47
ontological and epistemological changes in
diseases 48–9, 56–7
population-based medical screening 2, 5
potential contribution of sociological work 1
  barriers to research and analysis 7–8
dilemmas and challenges 4–5
  work on screening to date 5–7
  range of programmes 2
Wilson and Jungner’s principles 3, 47, 56
self-determination 122
social characteristics of patients 4, 5, 11, 107, 109, 115, 117, 118
social epidemiology 94
social innovation 61, 69, 84
sociology
  potential contribution to work on screening 1
  barriers to research and analysis 7–8
dilemmas and challenges 4–5
  work on screening to date 5–7
  sub-disciplines 1, 7
sonography see ultrasound
statistical panic 43
statistical risk 33, 34
surveillance medicine 5, 21, 27, 33, 91
social and political causes of disease 94
syphilis 19, 20
TB screening 11, 18, 20, 22
migrant screening
  active screening 97, 99, 100
  adverse conditions of care 99, 100, 101
  at-entry 97, 98
  definition of at-risk groups 93, 97, 100
  exclusionary policies 99, 100, 101
  humanitarian care-giving 97, 98, 99
  legalism 95, 97
  local know-how 96
  mandatory declarations 93, 94, 100
  multi-resistance 99
  outreach screening 95, 96, 98
  political conditions 90
  practical problems 91
  preventive measures 93, 94
  Roma communities 95, 96, 97, 98, 99, 100
  social information 93, 94, 100
  treatment failure 99
  undocumented migrants 93, 94, 95, 96, 97
  vulnerable migrants 95, 96, 97, 98, 99, 100, 101
targeted screening 90
Wolfheze Workshop 93
technologies 6, 8, 10
  bridging work see bridging work
cancer screening 60
governance 61, 68, 69, 70
Index

technologies (cont’d)
  ontological and epistemological changes in diseases 49, 56–7
  social innovation 61, 69, 84
  trajectory from bench to practice 76
  ultrasound see ultrasound
  X-rays 17–18, 19, 20, 91, 95, 98
  triangulation 76
  tuberculosis see TB screening

UK National Screening Committee 2, 3, 6, 63
ultrasound 11, 12
  antenatal screening 116, 124–7
    bonding scans 11, 12, 136, 138–40, 142, 146, 147
    collaborative coding 142–6, 147
    communicating risk with care 127–31, 132
    feminist critiques 136, 137, 139–40, 142, 145
    fetal facial expressions 140, 144, 147
    fetal personality 143–4
    fetal resemblance 142–3
    medical and social meanings 137–8, 146, 148
    potential harm 138, 139
  sonographer as expert guide 141–2, 146–7
  sonographers’ body language 127
  speaking to and for the fetus 144–5
  technological and embodied knowledge 145–6, 147, 148
  uncertainty 7, 9, 10, 39–40, 42, 47
    prostate-specific antigen tests 40, 42, 62, 64, 68
    uptake see attendance; non-attendance

vector-borne diseases 18
venereal disease 19
vulnerability 39–40, 42
  see also measured vulnerability

white coat hypertension 25
Wilson and Jungner’s principles of screening 3, 47, 56
World Health Organization 47

X-rays 17–18, 19, 20, 91, 95, 98

zur Hausen, Harald 77